For decades, researchers have dreamed of a way to prevent breast cancer before it even begins. Now, that dream may be closer than ever to reality.
A new breast cancer vaccine, developed by Anixa Biosciences in partnership with Cleveland Clinic, has just completed Phase 1 human trials and is moving into Phase 2—an ambitious step toward what scientists hope will become the world’s first preventative vaccine for triple-negative breast cancer (TNBC), one of the deadliest and most difficult-to-treat forms of the disease.
And unlike other cancer treatments, this one doesn’t just try to fight tumors. It aims to teach the immune system to stop them from forming in the first place.
Redefining Protection: What a Breast Cancer Vaccine Could Do for the Future
Traditional vaccines train the immune system to fight viruses and bacteria. But cancer—because it originates in the body’s own cells—is trickier. That’s where this vaccine is different.
It targets a milk-related protein called alpha-lactalbumin, which is present during lactation but disappears in normal tissue afterward. In about 70% of TNBC cases, however, this protein reappears. That’s the red flag. The vaccine trains the immune system to treat alpha-lactalbumin as a threat—so if a tumor begins to express it, the body can destroy those cells before they grow.
In the Phase 1 trial, 16 women who had completed treatment for TNBC received a series of three shots spaced two weeks apart. By the end of the study, 12 showed strong T-cell responses—signs that their immune systems had been activated against the target protein. Even more encouraging? There were no major side effects.
See also: New Brain Implant Translates Thoughts to Words in Real Time—And Even Recreates Your Voice
A Legacy That Started With One Patient
The first person to ever receive this vaccine was Jennifer Davis, a registered nurse and breast cancer survivor. Diagnosed with TNBC at 41, she joined the trial after reading about the vaccine’s success in animal studies.
“This is how we advance medicine,” she said at the time. “I’m just beyond grateful.”
Jennifer received the lowest dose possible in the earliest stage of testing. Tragically, her cancer returned. But even in her final days, she urged her community not to lose hope.
“There are so many women out there that we need to save,” she said.
Jennifer passed away in April 2024. But her impact on the future of cancer prevention lives on.
What Comes Next
The Phase 2 trial will include 600 women, half receiving the vaccine and half a placebo. If the results confirm what the early trials suggest—strong immune activation, safety, and a reduction in recurrence—researchers hope to seek FDA approval within five years.
Dr. Amit Kumar, CEO of Anixa Biosciences, sees even bigger possibilities on the horizon.
“We want to move beyond recurrence prevention to primary prevention,” he said. “We’re teaching the immune system to destroy the cells that can grow a tumor. That’s exactly the goal.”
See also: Artificial Blood That Works for Everyone? Japan’s Already Testing It
A Future Without Breast Cancer?
Triple-negative breast cancer accounts for about 10–15% of all breast cancers, yet it carries one of the lowest survival rates. It grows quickly, resists many traditional treatments, and is more likely to return even after aggressive therapy.
But if this vaccine succeeds, it could transform the very way we think about cancer—shifting from treatment to true prevention.
For the 1 in 8 women in the U.S. at risk of developing breast cancer, and for the families who’ve watched a loved one fight it, the hope is real. And it began with a simple idea: give the immune system a better target—and a chance to fight back before it’s too late.
